Langerhans cell histiocytosis
Conditions
Interventions
6-mercaptopurine:The single system involvement group, the bone involvement group with central risk and the multi-system involvement group were randomly divided into two groups: the maintenance treatme
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed LCH;Diagnostic criteria: all patients required pathological results of lesion biopsy, CD1a positive and/or CD207 (Langerin) positive immunohistochemical staining; 2. Aged <18 years; 3. Signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Received chemotherapy before; 2. Those who are allergic to the drugs used in the program; 3. Particicpated in other clinical researchers at the same time; 4. Unable to follow the prescribed treatment schedule due to personal reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD1a+CD207+ of Proliferative langerhans cells;reduction of complete blood count;serum biochemical index;coagulation function;urine specific gravity;Urine osmotic pressure;Rapidly rising of Soluble CD25;CD1a+CD207+ cells in bone marrow cytology;hepatosplenomegaly;Swelling of celiac lymph nodes;Presence of lesion;pulmonary function;X-ray of whole body skeleton;Pituitary stalk thickened, posterior lobe signal disappeared or weakened;presence of lesion bones;Hearing test;Intraocular pressure, fundus, visual acuity;Detection of BRAF gene mutation; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD1a+CD207+ S100+;lung biopsy;Spine MRI;Temporal CT, Orbital CT, Maxillary CT, Cervical CT;Temporal CT, Orbital CT, Maxillary CT, Cervical CT, Thyroid Function, ACTH, Cortisol, IGF-1, Growth Hormone and Sex Hormone;Endoscopy and biopsy of digestive tract; | — |
Countries
China
Contacts
Public ContactTianyou Wang, Rui Zhang
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed